Avillion I (Pfizer)

Avillion is focused on clinical co-development and financing of late-stage therapeutics. The company formed a deal with Pfizer and they have received US approval for Pfizer's Bosulif® (bosutinib) as a first-line treatment for chronic myelogenous leukaemia.